Sublime provides an advanced manufacturing technology for particle engineering and formulation of small-molecule active pharmaceutical ingredients.

Sublime is a member of the US FDA’s Emerging Technology Program, intended for technologies that show potential to improve drug products and their manufacturing processes. Support to advance Sublime’s technology includes a grant from the Bill & Melinda Gates Foundation, which provides funding for a research project applying Sublime’s technology to medicines for global health. Development also advances via projects for clients including pharmaceutical companies and non-profit, government-funded drug developers.

Sublime’s scalable, distributed, automatable, waste-free, solvent-free particle engineering technology enables continuous or batch processing of enhanced drug substance and drug product. The technology can support any dosage form (e.g., solid tablets, thin-film coatings, transdermal patches, long-acting injectables, dry powder inhaled drugs, etc.) while offering increased bioavailability, excellent scaling flexibility, high drug loading, rapid cocrystal generation, and novel particle morphologies.